Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.79 |
| ▸ | KLK7 | P49862 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938756 | 0.94 | PTPN1 (0.88) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Glycitein SCHEMBL29497281 | 0.90 | HDAC6 (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Glycitein SCHEMBL7733712 | 0.90 | HDAC6 (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Glycitein SCHEMBL19720 | 0.90 | HDAC6 (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Castanin SCHEMBL572274 | 0.88 | RAB9A (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Calycosin SCHEMBL73013 | 0.87 | KDM4E (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| Calycosin SCHEMBL30335127 | 0.87 | KDM4E (1.00) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| SCHEMBL10560560 | 0.87 | PTPN1 (0.77) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| SCHEMBL5426172 | 0.87 | HDAC6 (0.81) | PTPN1PPARGHDAC6RAB9AKLK7 | |
| SCHEMBL10441842 | 0.86 | KDM4E (0.80) | PTPN1PPARGHDAC6RAB9AKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2024054688-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2024049361-A1 | MIXTURES OF CANNABINOID-BASED COMPOSITIONS AND ACTIVE SUBSTANCES FROM OTHER GENERA FOR MEDICAL APPLICATIONS AND ASSOCIATES | FAIR MED (THAILAND) COMPANY LIMITED (TH) | 2024-03-07 | — | — | WO | claimed |
| CN-106727776-A | Pharmaceutical composition for treating fibroid | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106619791-A | Pharmaceutical composition for treating mumps and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-106109585-A | Prevent and treat the pharmaceutical composition of breast carcinoma | 济南星懿医药技术有限公司 | 2016-11-16 | — | — | CN | claimed |
| CN-106038877-A | Drug compound for treating suppurative otitis media of children and preparation method thereof | 济南星懿医药技术有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-105708871-A | Medicinal composition for preventing and treating depression | 济南星懿医药技术有限公司 | 2016-06-29 | — | — | CN | claimed |
| CN-105535059-A | Medicine composition for treating encephalatrophy | JINAN XINGYI MED TECH CO LTD | 2016-05-04 | — | — | CN | claimed |
| CN-105326874-A | Medicine composition for treating dyspepsia | JINAN XINGYI MED TECH CO LTD | 2016-02-17 | — | — | CN | claimed |
| CN-105288201-A | Pharmaceutical composition for treating IIIB type prostatitis and preparation method thereof | JINAN XINGYI MED TECH CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-105250500-A | Medicine composition for treating dyspepsia | JINAN XINGYI MED TECH CO LTD | 2016-01-20 | — | — | CN | claimed |
| EP-1708695-A1 | COMPOSITIONS AND METHOD FOR TREATMENT OF STEROID/NUCLEAR RECEPTOR-MEDIATED DISEASES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2006-10-11 | — | — | EP | claimed |
| WO-2005053724-A1 | COMPOSITIONS AND METHOD FOR TREATMENT OF STEROID/NUCLEAR RECEPTOR-MEDIATED DISEASES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2005-06-16 | — | — | WO | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4665318-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | Native Code Bio, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2005053724-A1 | COMPOSITIONS AND METHOD FOR TREATMENT OF STEROID/NUCLEAR RECEPTOR-MEDIATED DISEASES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2005-06-16 | — | — | WO | disclosed |
| US-20050118290-A1 | Compositions and method for treatment of steroid/nuclear receptor-mediated diseases | UNIVERSITY OF SINGAPORE (SG) | 2005-06-02 | — | — | US | disclosed |
| US-20040128714-A1 | Method of decreasing liquiritigenin-derived isoflavones relative to total isoflavones in plants and plants producing reduced ratio of liquiritigenin-derived isoflavones relative to total isoflavones | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050118290-A1 | Compositions and method for treatment of steroid/nuclear receptor-mediated diseases | PPARG, PPARA, NR1H2 | PTPN1 580/4885PPARG 1/4885HDAC6 3648/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | PTPN1 4587/4885PPARG 1223/4885HDAC6 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.